QuidelOrtho Grants Restricted Stock Units to CFO Under Nasdaq Listing Rule

QuidelOrtho Announces Important Inducement Grant

On July 15, 2026, QuidelOrtho Corporation, a prominent global player in the diagnostic solution arena, revealed the approval of a significant inducement grant. This strategic decision was made by the Compensation Committee of the Board of Directors, targeting Micah Young, the newly appointed Chief Financial Officer and principal financial officer of the company.

The inducement grant encompasses the issuance of restricted stock units (RSUs) totaling 356,555 shares of common stock. This initiative aligns with QuidelOrtho's 2026 Inducement Plan, designed specifically as a persuasive measure for individuals who are either new to the company or have re-entered its workforce after a legitimate hiatus. This move is in accordance with Nasdaq Listing Rule 5635(c)(4), meant to attract and retain top talent.

Details of the Grant

The RSUs are set to become effective on the grant date, July 15, 2026, with a vesting schedule that stretches over three years. More specifically, these stocks will vest in equal annual increments, contingent on Mr. Young's continuous employment with QuidelOrtho during each vesting period. This structured approach aims not only to incentivize long-term commitment to the company but also to highlight the importance of stable leadership in steering the organization towards future growth.

QuidelOrtho proudly positions itself as a pioneer in advancing diagnostic capabilities, ultimately striving for a healthier tomorrow. The company’s focus encompasses a wide array of platforms, facilitating swift and accurate diagnostic results that improve patient care—from immediate point-of-care assessments to hospital lab environments. This commitment underscores the urgent need for innovative healthcare solutions in today's evolving medical landscape.

About QuidelOrtho Corporation

With its expertise in various testing modalities including clinical chemistry, immunoassay, immunohematology, and molecular diagnostics, QuidelOrtho Corporation continues to be a leading force in the industry. Their capabilities not only promise rapid results but also ensure that patients receive the highest standards of care. They maintain an exceptional legacy of innovation, which has been instrumental in connecting healthcare providers with the necessary insights to make informed decisions.

The introduction of the RSUs for Micah Young marks an important milestone not just for him, but for the company as a whole, reflecting its ongoing strategy to foster a conducive environment for success amongst its leadership team.

In concluding this announcement, QuidelOrtho invites those interested to learn more about their offerings and corporate vision by visiting their website at quidelortho.com and engaging with their communities on platforms such as LinkedIn, Facebook, and X.

QuidelOrtho remains resolute in its mission to enhance diagnostics, ensuring that they are not just solutions, but bridges to better health for everyone.

In addition to this news, the corporate entity also reaffirms its commitment to educational and communicative initiatives that underpin their innovations. As they look forward to unveiling more advancements, the organization stands firm on prioritizing community health and robust patient outcomes through integral partnerships and industry collaborations.